ストックスクリーナーアプリを入手
3.20
2.56%
0.08
アフターアワーズ：
3.26
0.06
+1.87%
前日終値:
$3.12
開ける：
$3.18
24時間の取引高:
31,457
Relative Volume:
0.21
時価総額：
$1.14B
収益：
$890.87M
当期純損益:
$-115.85M
株価収益率:
-9.8129
EPS:
-0.3261
ネットキャッシュフロー:
$-104.29M
1週間 パフォーマンス:
+7.38%
1か月 パフォーマンス:
+23.55%
6か月 パフォーマンス:
-4.33%
1年 パフォーマンス:
-23.26%
1日の値動き範囲:
$3.105
$3.20
1週間の範囲:
$2.90
$3.218
52週間の値動き範囲:
$2.308
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, ZTS, TEVA, HLN, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.20 | 1.11B | 890.87M | -115.85M | -104.29M | -0.3261 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 再開されました | H.C. Wainwright | Buy |
| 2026-02-03 | 開始されました | Berenberg | Buy |
| 2025-04-24 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-10-07 | ダウングレード | Jefferies | Buy → Hold |
| 2024-08-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-07-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-04-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-08 | アップグレード | Citigroup | Neutral → Buy |
| 2023-04-04 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-16 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-08-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2022-01-07 | 再開されました | Citigroup | Neutral |
すべてを表示
Evotec Se Adr (EVO) 最新ニュース
Boyd Gaming posts downbeat Q1 results, joins Coursera, Evotec and other big stocks moving lower in Friday's pre-market session - MSN
Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today - AD HOC NEWS
Evotec nominates Wolfgang Hofmann to supervisory board By Investing.com - Investing.com Australia
Evotec nominates Wolfgang Hofmann to supervisory board - Investing.com
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin By Investing.com - Investing.com Australia
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday - Benzinga
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin - Investing.com
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough for biotech recovery? - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery pipeline strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for steady ups - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for biotech re - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock biotech upside? - AD HOC NEWS
Evotec appoints Ingrid Müller as chief operating officer - Investing.com
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock new upside? - AD HOC NEWS
Evotec Q4 2025 slides: strong finish masks segment headwinds By Investing.com - Investing.com Australia
BofA reiterates Evotec stock Underperform rating on execution concerns - Investing.com
Evotec (NASDAQ: EVO) pivots to asset-light model and boosts 2025 liquidity - Stock Titan
Evotec Q4 2025 slides: strong finish masks segment headwinds - Investing.com
Earnings call transcript: Evotec SE ADR Q4 2025 sees revenue growth, stock surges - Investing.com
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal By Investing.com - Investing.com South Africa
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal - Investing.com
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Benzinga
Evotec's B2B Partner Search Initiative: Unlocking Strategic Collaborations in Drug Discovery for Nor - AD HOC NEWS
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026 - ChartMill
Evotec appoints Ashiq Khan as chief commercial officer - Investing.com
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer - ChartMill
Evotec SE Stock: Drug Discovery Leader Faces Restructuring Challenges Ahead of Key Earnings - AD HOC NEWS
Evotec SE stock faces pressure amid biotech sector volatility and partnership updates - AD HOC NEWS
Evotec SE Stock Faces Pressure Amid Biotech Sector Headwinds and Pipeline Updates in Q1 2026 - AD HOC NEWS
JustEvotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - ChartMill
Breaking News! Takeover speculation? BioNTech, Evotec, Vidac Pharma - news.financial
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Evotec Aktie | DE0005664809 | ETR:EVT | News & Aktienkurs | FRA:EVT - LYNX Online Broker
Evotec shares surge 8% as Berenberg initiates with “buy” on partner value By Investing.com - Investing.com South Africa
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? - Finviz
Financial Review: Evotec (NASDAQ:EVO) & Savara (NASDAQ:SVRA) - Defense World
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Chartmill
Taxes of Evotec SE Sponsored ADR – LSX:A0QZ3J - TradingView — Track All Markets
EvotecHow Low A Company May Go While Still Being Attractive (NASDAQ:EVO) - Seeking Alpha
Evotec Se Adr (EVO) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):